“Spark” PtMnIr Nanozymes for Electrodynamic‐Boosted Multienzymatic Tumor Immunotherapy
Source abstract
Abstract
Abstract Multienzyme‐mimicking redox nanozymes capable of efficient reactive oxygen species (ROS) generation and cellular homeostasis disruption are highly pursued for cancer therapy. However, it still faces challenges from the complicate tumor microenvironment (TME) and high chance for tumor metastasis. Herein, well‐dispersed PtMnIr nanozymes are designed with multiple enzymatic activities, including catalase (CAT), oxidase (OXD), superoxide dismutase (SOD), peroxidase (POD), and glutathione peroxidase (GPx), which continuously produce ROS and deplete glutathione (GSH) concurrently in an “inner catalytic loop” way. With the help of electrodynamic stimulus, highly active “spark” species (Ir3+ and Mn3+) are significantly increased, resulting in an effective cascade enzymatic and electrodynamic therapy. Moreover, the cyclic generation of ROS can also facilitate ferroptosis and apoptosis in tumor cells, boosting synergistic therapy. Importantly, lung metastasis inhibition is found, which confirms efficient immunotherapy by the combined effect of immunogenic cell death (ICD) and Mn2+‐induced cyclic guanosine monophosphate (GMP)–adenosine monophosphate (AMP) synthase (cGAS)–stimulator of interferon genes (cGAS–STING) pathway, contributing great potential in the treatment of malignant tumors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Health Science and Environmental Engineering Shenzhen Technology University Shenzhen 518118 P. R. China
Department of Materials Science and Engineering Southern University of Science and Technology Shenzhen 518055 P. R. China
Pingshan Translational Medicine Center Shenzhen Bay Laboratory Shenzhen 518132 P. R. China
Funding
National Natural Science Foundation of China
References (53)
Show source-provided references
1. 10.1158/2159-8290.CD-21-092210.1158/2159-8290.CD-21-0922 ↗
2. 10.1186/s12943-016-0550-210.1186/s12943-016-0550-2 ↗
3. 10.3390/pharmaceutics1309133210.3390/pharmaceutics13091332 ↗
4. 10.1002/anie.20190682310.1002/anie.201906823 ↗
5. 10.1016/j.biomaterials.2020.12047410.1016/j.biomaterials.2020.120474 ↗
6. 10.1158/2159-8290.CD-20-180810.1158/2159-8290.CD-20-1808 ↗
7. 10.1039/C8CS00718G10.1039/C8CS00718G ↗
8. 10.1021/acs.chemrev.8b0067210.1021/acs.chemrev.8b00672 ↗
9. 10.1002/adma.20221121010.1002/adma.202211210 ↗
10. 10.1016/j.ccr.2022.21482110.1016/j.ccr.2022.214821 ↗
11. 10.1002/adma.20220323610.1002/adma.202203236 ↗
12. 10.1039/D2NR03479D10.1039/D2NR03479D ↗
13. 10.1002/adma.20210705410.1002/adma.202107054 ↗
14. 10.1039/D3TB00220A10.1039/D3TB00220A ↗
15. 10.1039/D2NR02908A10.1039/D2NR02908A ↗
16. 10.1021/jacs.2c1368910.1021/jacs.2c13689 ↗
17. 10.3390/ma1501033710.3390/ma15010337 ↗
18. H.Wang Y.Wang L.Lu Q.Ma R.Feng S.Xu T. D.James L.Wang Adv. Funct. Mater2022 32 2200331.10.1002/adfm.202200331 ↗
19. 10.1021/jacs.2c1294210.1021/jacs.2c12942 ↗
20. 10.1002/adfm.20221474910.1002/adfm.202214749 ↗
21. 10.1002/adma.20180680310.1002/adma.201806803 ↗
22. 10.1093/annonc/mdz10810.1093/annonc/mdz108 ↗
23. 10.1038/s41577-021-00524-z10.1038/s41577-021-00524-z ↗
24. 10.1186/s13045-020-00916-z10.1186/s13045-020-00916-z ↗
25. 10.1038/s41422-020-00395-410.1038/s41422-020-00395-4 ↗
26. 10.1002/anie.20200511110.1002/anie.202005111 ↗
27. 10.1039/D0NR02736G10.1039/D0NR02736G ↗
28. 10.1002/ange.20211722910.1002/ange.202117229 ↗
29. 10.1016/j.biomaterials.2022.12157210.1016/j.biomaterials.2022.121572 ↗
30. 10.1002/ange.20191614210.1002/ange.201916142 ↗
31. 10.1016/j.biomaterials.2020.11984810.1016/j.biomaterials.2020.119848 ↗
32. 10.1021/acsnano.1c1045010.1021/acsnano.1c10450 ↗
33. 10.1016/j.chempr.2020.06.02410.1016/j.chempr.2020.06.024 ↗
34. 10.1093/nsr/nwaa16010.1093/nsr/nwaa160 ↗
35. 10.1083/jcb.20180416110.1083/jcb.201804161 ↗
36. 10.1002/smll.20220133310.1002/smll.202201333 ↗
37. 10.1002/smll.20170215610.1002/smll.201702156 ↗
38. 10.1021/acsnano.1c0854410.1021/acsnano.1c08544 ↗
39. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
40. 10.1038/s41571-020-00462-010.1038/s41571-020-00462-0 ↗
41. 10.1016/j.freeradbiomed.2018.09.01410.1016/j.freeradbiomed.2018.09.014 ↗
42. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
43. 10.1002/adma.20220540910.1002/adma.202205409 ↗
44. 10.1038/nri159410.1038/nri1594 ↗
45. 10.1038/nbt0207-19210.1038/nbt0207-192 ↗
46. 10.1038/s41416-018-0328-y10.1038/s41416-018-0328-y ↗
47. 10.1002/adma.20200848110.1002/adma.202008481 ↗
48. 10.1002/adma.20210257010.1002/adma.202102570 ↗
49. 10.1038/s41586-019-1170-y10.1038/s41586-019-1170-y ↗
50. 10.1126/sciadv.aax134610.1126/sciadv.aax1346 ↗
51. 10.1002/adma.20220976510.1002/adma.202209765 ↗
52. 10.1002/adma.20190163310.1002/adma.201901633 ↗
53. 10.1002/adfm.20230083310.1002/adfm.202300833 ↗